Fulltext

Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia : Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zürich, Switzerland, bet ween 1990 and 1996

Dazzi, H. ; Kaufmann, K. ; Follath, F.

In: Annals of Oncology, 2001, vol. 12, no. 7, p. 963-966

Aggiungi alla tua lista
    Titre
    • Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia
      Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zürich, Switzerland, bet ween 1990 and 1996
    Auteur
    • Dazzi, H.. Department for Internal Medicine, University Hospital, Zürich, Switzerland
    • Kaufmann, K.. Department for Internal Medicine, University Hospital, Zürich, Switzerland
    • Follath, F.. Department for Internal Medicine, University Hospital, Zürich, Switzerland
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • Annals of Oncology, 2001, vol. 12, no. 7, p. 963-966. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:296418
    Summary
    Background: Acute cardiotoxicity due to anthracyclines is a rare, but life-threatening event. Interindividual sensitivity to anthracyclines is highly variable and cannot be predicted for the individual patient. Patients and methods: This is a retrospective study. Medical charts and autopsy report of patients treated for acute leuke mia between 1990 and 1996 at the University Hospital of Zürich, Switzerland were reviewed and searched for anthracycline-associated acute cardiotoxicity. Patients with pre-existing heart disease known to be associated with cardiotoxicity were excluded. Results: Seven patients treated for leukemia with proven anthracycline-associated acute cardiotoxicity were included. In six patients the direct cause of death was acute cardiotoxicity due to the treatment. One patient recovered from cardiac failure but died a few months later from refractory leukemia. Clinical symptoms were those of a heart failure. Pathological findings were dilatative cardiac hypertrophy and pericardial effusion. Microscopically the typical findings of myocardial fibrosis and perinuclear vacuolisated myocytes were seen. Conclusions: The awareness of acute adverse effects on cardiac performance by anthracyclines faciliates early recognition and prevention of heart failure. Reliable tests are needed for the early diagnosis of subclinical myocardial damage in order to identify patients at risk